drugset
drugset / Trial / NCT07238569

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

NCT07238569 ↗

Phase 3 Not yet recruiting 516 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA positivity or stable disease after three IC cycles. The control arm received adjuvant adebrelimab, while the experimental arm received adebrelimab plus capecitabine.

Timeline

Start
2025-12-01
Primary completion
2029-12-01
Completion
2031-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody 1200 mg —
Subject Capecitabine Small molecule 650 mg/m2 Oral
Background Cisplatin Other / unclassified 100 mg/m2 —

Indications

nasopharyngeal carcinoma